SEC-sourced researchBeta
DNA
Ginkgo Bioworks Holdings, Inc.
Company comparison ↗
Data passport
- CIK
- 0001830214
- Exchange
- NYSE
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Oct 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 251,455,000.0000 | Feb 26, 2026 |
| December 2024 | 227,043,000.0000 | Feb 26, 2026 |
| December 2025 | 170,155,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 170,155,000.0000 | -312,763,000.0000 | -171,059,000.0000 | 1,119,696,000.0000 | 611,106,000.0000 | Feb 26, 2026 |
| December 2024 | 227,043,000.0000 | -547,029,000.0000 | -319,585,000.0000 | 1,377,449,000.0000 | 661,391,000.0000 | Feb 26, 2026 |
| December 2023 | 251,455,000.0000 | -892,869,000.0000 | -295,500,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $170.16M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $227.04M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$312.76M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$171.06M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $1.12B | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $611.11M | December 2025 | Feb 26, 2026 | 10-K |